Pieris Pharmaceuticals, Inc. (PIRS)
NASDAQ: PIRS · IEX Real-Time Price · USD
8.57
-1.13 (-11.65%)
At close: Jul 2, 2024, 3:50 PM
8.58
+0.01 (0.12%)
After-hours: Jul 2, 2024, 7:33 PM EDT
Pieris Pharmaceuticals Revenue
Pieris Pharmaceuticals had revenue of $40.93M in the twelve months ending March 31, 2024, with 142.89% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $53.00K, a -97.26% decrease year-over-year. In the year 2023, Pieris Pharmaceuticals had annual revenue of $42.81M with 65.28% growth.
Revenue (ttm)
$40.93M
Revenue Growth
+142.89%
P/S Ratio
0.28
Revenue / Employee
$889,717
Employees
46
Market Cap
11.31M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 42.81M | 16.91M | 65.28% |
Dec 31, 2022 | 25.90M | -5.52M | -17.56% |
Dec 31, 2021 | 31.42M | 2.10M | 7.14% |
Dec 31, 2020 | 29.32M | -16.96M | -36.64% |
Dec 31, 2019 | 46.28M | 17.18M | 59.03% |
Dec 31, 2018 | 29.10M | 3.83M | 15.14% |
Dec 31, 2017 | 25.28M | 19.44M | 333.46% |
Dec 31, 2016 | 5.83M | 2.90M | 98.88% |
Dec 31, 2015 | 2.93M | -2.43M | -45.35% |
Dec 31, 2014 | 5.37M | -7.06M | -56.83% |
Dec 31, 2013 | 12.43M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Centogene | 53.93M |
STRATA Skin Sciences | 32.55M |
RedHill Biopharma | 6.53M |
Elevai Labs | 2.18M |
Longeveron | 978.00K |
Nexalin Technology | 158.86K |
Organovo Holdings | 109.00K |
PIRS News
- 2 months ago - Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split - Accesswire
- 3 months ago - Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential - Accesswire
- 11 months ago - Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific - Accesswire
- 1 year ago - Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring - Accesswire
- 1 year ago - Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study - Accesswire
- 1 year ago - Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference - Accesswire
- 1 year ago - Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference - Accesswire
- 1 year ago - Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference - Accesswire